Climb Bio reports Q4/FY2025 results; cash $160.7M; pipeline trials on track with data in 2026

Climb Bio, Inc.

Cash, cash equivalents, and marketable securities $160.7M as of Dec 31, 2025; expected runway into 2028.
FY2025 R&D expense $46.7M vs $14.3M in FY2024; G&A expense $21.2M vs $16.0M.
Budoprutug SC formulation Phase 1 dosing completed; data expected H1 2026.
Budoprutug pMN, ITP, SLE trials ongoing; initial efficacy data expected H2 2026.
CLYM116 Phase 1 healthy volunteer study enrollment ongoing; initial data expected mid-2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Climb Bio, Inc. reported financial results for fourth quarter and full year ended December 31, 2025.

Period: fourth quarter and full year ended December 31, 2025
Result: reported results

Exact text from the filing

Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business updates.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Climb Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-092520

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.